// App-Quantinova.ai

: Use of prostate cancer subtyping by gene expression to predict response to radiation and chemohormonal therapies.

Researchers

Presenter

  • Adam B Weiner

Principal Investigators

  • Alexander K. Hakansson

  • Xin Zhao

  • James Alexander Proudfoot

  • JJ Haijing Zhang

  • R. Jeffrey Karnes

  • Robert Benjamin Den

  • Amar Upadhyaya Kishan

  • Robert Evan Reiter

  • Anis Hamid

  • Ashley Ross

  • Phuoc T. Tran

  • Melvin L.K. Lee Kiang Chua

  • Daniel Eidelberg Spratt

  • Gerhardt Attard

  • Tamara L. Lotan

  • Christopher J Sweeney

  • Elai Davicioni

  • Edward M. Schaeffer

Medical Centers

  • UCLA, Los Angeles, CA

  • Mayo Clinic, Rochester, MN

  • UCLA Care Center, Los Angeles, CA

  • Veracyte, Inc, San Diego, CA

  • National Cancer Centre Singapore, Singapore, Singapore

  • Northwestern University, Feinberg School of Medicine, Chicago, IL

  • University Hospitals Cleveland Medical Center / Case Western Reserve University School of Medicine, Cleveland, OH

  • University of Maryland, Baltimore, MD

  • University of California, Los Angeles, Los Angeles, CA

  • Johns Hopkins University School of Medicine, Baltimore, MD

  • Jefferson Kimmel Cancer Center, Philadelphia, PA

  • Veracyte, Inc, Vancouver, BC, Canada

  • The Institute of Cancer Research, King's College, London, United Kingdom

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • United Kingdom

  • Singapore

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Docetaxel

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved